Monte Rosa Therapeutics (GLUE)
US Market

Monte Rosa Therapeutics (GLUE) Financial Statements


Monte Rosa Therapeutics Financial Overview

Monte Rosa Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.69; its P/E ratio is -2.34; Monte Rosa Therapeutics is scheduled to report earnings on March 26, 2024, and the estimated EPS forecast is $-0.39. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue----$ 0.00
Gross Profit-----
EBIT$ -34.71M$ -34.73M$ -34.12M$ -31.14M$ -28.36M
EBITDA--$ -32.92M$ -31.59M$ -27.33M
Net Income Common Stockholders$ -34.71M$ -35.18M$ -31.68M$ -29.03M$ -27.32M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 178.48M$ 203.07M$ 232.69M$ 263.79M$ 272.15M
Total Assets$ 252.10M$ 278.62M$ 309.03M$ 342.39M$ 357.60M
Total Debt$ 46.40M$ 47.03M$ 46.16M$ 47.00M$ 45.66M
Net Debt$ -132.08M$ -156.03M$ -186.53M$ -216.78M$ -226.49M
Total Liabilities$ 67.58M$ 64.96M$ 65.30M$ 70.98M$ 66.51M
Stockholders Equity$ 184.52M$ 213.61M$ 243.73M$ 271.41M$ 291.09M
Cash Flow-
Free Cash Flow--$ -32.54M$ -31.23M$ -22.00M
Operating Cash Flow$ -24.71M-$ -23.36M$ -23.96M$ -20.60M
Investing Cash Flow$ 35.63M-$ 20.33M$ -53.94M$ 29.49M
Financing Cash Flow$ 1.10M-$ 18.00K$ 20.43M$ -217.00K
Currency in USD

Monte Rosa Therapeutics Earnings and Revenue History

Monte Rosa Therapeutics Debt to Assets

Monte Rosa Therapeutics Cash Flow

Monte Rosa Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis